https://www.selleckchem.com/products/BIBF1120.html
Thyroid autoantibodies are variably present and are not clearly related to the risk or progression of thyroid dysfunction following treatment with an immune checkpoint inhibitor. Observational data suggest that development of immune checkpoint inhibitor-associated thyroiditis may predict improved survival. CONCLUSIONS Immune checkpoint inhibitor-associated thyroiditis is a distinct clinical entity. Mechanisms underlying aetiology remain largely unknown. Awareness amongst health professionals is important to limit morbidity and avoid un